Abdul Mannan: A Red Eye, a Blood Clot, and Ibrutinib – The Clinical Tightrope
Abdul Mannan, Consultant Hematologist at Betsi Cadwaladr University Health Board, shared a post on LinkedIn:
“A red eye. A blood clot. And ibrutinib. This is the clinical tightrope.
My SLL patient was on ibrutinib 420 mg for her disease and therapeutic anticoagulation for a massive PE.
Then her eye turned red. Spontaneous subconjunctival haemorrhage. No major bleeding anywhere.
The question every haematologist dreads: Do I stop something? And if so, what?
Here is the answer the evidence gives us.
The red eye is Grade 1. It is minor. It is expected. Ibrutinib knocks out BTK and Tec kinase together, crippling platelet adhesion via GPVI/collagen and GPIb/vWF pathways.
The result is platelet dysfunction, not thrombocytopenia. Mucocutaneous bleeding happens in up to 67% of patients on ibrutinib. A subconjunctival bleed is part of that story.
But stacking anticoagulation on top? That is where the real risk lives.
What the numbers tell us (Roccograndi et al., Leukemia & Lymphoma 2023, n=64 CLL/SLL patients):
- Apixaban used with ibrutinib: 6% major bleeding
- Rivaroxaban used with ibrutinib: 18% major bleeding
- Enoxaparin used with ibrutinib: 0% (small numbers, but reassuring)
Warfarin: contraindicated, full stop
Ibrutinib combined with DOAC and clopidogrel:
one fatal intracranial haemorrhage
Wang et al. meta-analysis (Frontiers in Pharmacology 2020, 11 RCTs, 4,288 patients) showed ibrutinib triples overall bleeding risk in CLL patients.
So what did I do?
Continued ibrutinib. Continued anticoagulation. The PE does not forgive you for stopping. Checked she was on apixaban not rivaroxaban. Checked renal function. Removed every antiplatelet from her list. Educated her on CNS and GI red flag symptoms.
The infographic below tells the whole story in one page. Save it. Share it with your trainees.
- Bleed concern: LOW.
- Overall vigilance: HIGH.
Have you faced this combination in practice? What anticoagulant did you go with?”
Other posts featuring Abdul Mannan on Hemostasis Today.
-
Apr 29, 2026, 17:25Robert Brodsky: Ravulizumab Appears To Be Safe And Effective In Pregnancy
-
Apr 29, 2026, 16:53Chokri Ben Lamine: IV Iron Showdown – FCM vs Ferric Derisomaltose vs Iron Dextran
-
Apr 29, 2026, 16:46Deep Vein Thrombosis Risk in Jobs with Prolonged Sitting – NBCA
-
Apr 29, 2026, 16:41Vikramaditya Gangakar: Essential Pharmacy Facts You Should Know About Aspirin
-
Apr 29, 2026, 16:17W. Alberto Sifuentes Giraldo: Non-Criteria Manifestations of Antiphospholipid Syndrome
-
Apr 29, 2026, 16:12Mavis Agnes Kisakye: Concluding a Successful Entrepreneurs Training for Empowering Ptients’ Mothers
-
Apr 29, 2026, 15:48Kriti Batni: Happy to Share Current Use and Future Directions of Monoclonal Antibodies in Medicine Update 2026
-
Apr 29, 2026, 15:46Dima Shulkin: Comparing HALP and PIV for Mortality Prediction in ACS
-
Apr 29, 2026, 15:44Sonal Sonu: Securing First Prize in Research Oral Presentation at the CME